Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response

No AccessJournal of UrologyUrological Survey: Abstracts: Renal Tumors, Retroperitoneum, Ureter, and Urinary Diversion and Reconstruction1 Aug 1999Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response S.A. Rosenberg, J.C. Yang, D.E. White, and S.M. Steinberg S.A. RosenbergS.A. Rosenberg More articles by this author , J.C. YangJ.C. Yang More articles by this author , D.E. WhiteD.E. White More articles by this author , and S.M. SteinbergS.M. Steinberg More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68669-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response." The Journal of Urology, 162(2), p. 637 Surgery Branch, and Department of Biostatistics and Data Management Section, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 162Issue 2August 1999Page: 637 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information S.A. Rosenberg More articles by this author J.C. Yang More articles by this author D.E. White More articles by this author S.M. Steinberg More articles by this author Expand All Advertisement PDF downloadLoading ...